Ortho Clinical Diagnostics Holdings plc (OCDX)
| Market Cap | 4.33B |
| Revenue (ttm) | 1.97B |
| Net Income (ttm) | n/a |
| Shares Out | 235.13M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | 21.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,671,842 |
| Open | 18.54 |
| Previous Close | 18.58 |
| Day's Range | 18.23 - 18.72 |
| 52-Week Range | 15.14 - 22.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 27.11 (+44.8%) |
| Est. Earnings Date | Nov 3, 2021 |
About OCDX
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in b...
Financial Performance
In 2020, OCDX's revenue was $1.77 billion, a decrease of -1.96% compared to the previous year's $1.80 billion. Losses were -$211.90 million, 35.1% more than in 2019.
Financial StatementsNews
Ortho Clinical Diagnostics Announces Closing of Secondary Offering of Ordinary Shares and Full Exercise of Underwrite...
RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today annou...
Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares
RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today annou...
Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares
RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today annou...
Ortho Clinical Diagnostics to Participate in September Investor Conferences
RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that ...
Ortho Clinical Diagnostics Holdings Plc (OCDX) EVP, GC and Secretary Michael A..
Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocaps...
-- Ortho's new VITROS® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior CO...
Ortho Clinical Diagnostics Reports Second Quarter 2021 Results
Strong Revenue Growth Drives Financial Results
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada
RARITAN, N.J., July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTI...
Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021
RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results fo...
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Crit...
RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic ...
Ortho Clinical Diagnostics' COVID-19 Antibody Test Gets FDA Emergency Use Approval
The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics' (NASDAQ: OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test. The company says it the first quantitative COVID-19 IgG ...
Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization
- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians an...
Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific
RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, today announced its distribution agreem...
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
RARITAN, N.J., June 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX...
Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A N...
- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of a...
Ortho Clinical Diagnostics to Present at Upcoming Investor Conferences
RARITAN, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its ...
Ortho Clinical Diagnostics Reports First Quarter 2021 Results
First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 2021 Guidance First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 20...
Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark
- Ortho's VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization o...
Global Transfusion Medicine Leader Ortho Clinical Diagnostics Launches Next Gen ORTHO VISION® Swift Platform
ORTHO VISION is the leading choice for blood banks RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics compani...
Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of...
RARITAN, N.J., April 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious...
Ortho Clinical Diagnostics to Report First Quarter 2021 Results on May 5, 2021
RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results f...
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient...
RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for i...
Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA an...
- The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months RARITAN, N.J., M...
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Perf...
RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization fr...
REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results
Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%